bearish
TOT Biopharm (东曜药业) IPO: Valuation of Core Product TAB008, a Bevacizumab Biosimilar
548 Views13 Sep 2019 09:31
TOT Biopharm, a China-based clinical-stage biopharmaceutical company, plans to raise at least USD 100 million from its listing in its Hong Kong...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 2-minute read)
Discussions
(Paid Plans Only)
- TOT Biopharm (东曜药业) IPO: Valuation of Core Product TAB008, a Bevacizumab Biosimilar13 Sep 2019
- TOT Biopharm (东曜药业) IPO: An Unimpressive Pipeline12 Jul 2019
x